Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.…
Decoy Therapeutics: Q3 Earnings Snapshot
Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards
Decoy Therapeutics (NASDAQ: DCOY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 0.8294 USD on 20 November 2026, down 97.5% over 52 weeks. Its 52-week range is 0.8000 USD to 38.40 USD: the price is 97.8% below the high and 3.7% above the low.
Its market capitalisation is 1.98M USD.
Decoy Therapeutics reports return on equity of -212.6%.
It holds more cash than debt, a net cash position of 8.29M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 3.000 USD is 261.7% above the current price.